Hypertrophic obstructive cardiomyopathy—the role of myectomy and percutaneous septal ablation in drug-refractory disease

Background Hypertrophic cardiomyopathy (HCM) is caused by mutations in a number of genes. Its prevalence is 0.2% to 0.6%.